Domov › Rak dojke › Kalifornija › Mountain View
Klinične študije za Rak dojke v Mountain View, CA
26 študij za Rak dojke išče udeležence na lokacijah v Mountain View in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Vključevanje udeležencevFaza 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi stran
A Study of PHST001 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Stanford University School of Medicine, Palo Alto · 5 mi stran
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Vključevanje udeležencevFaza 3
- El Camino Hospital, Mountain View
- Palo Alto Medical Foundation, Mountain View
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Vključevanje udeležencevFaza 1/2
- Stanford Medicine Cancer Center, Stanford · 5 mi stran
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Vključevanje udeležencevFaza 3
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Vključevanje udeležencevFaza 1
- Stanford University Medical Center, Stanford · 5 mi stran
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Vključevanje udeležencevFaza 1
- Stanford University Medical Center, Stanford · 5 mi stran
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Vključevanje udeležencevFaza 3
- Stanford Cancer Center, Palo Alto · 5 mi stran
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Vključevanje udeležencevFaza 3
- Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto · 5 mi stran
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Vključevanje udeležencevFaza 3
- Stanford Women's Cancer Center, Palo Alto · 5 mi stran
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Vključevanje udeležencevFaza 1
- Stanford University Hospital, Stanford · 5 mi stran
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- Research Site, Palo Alto · 5 mi stran
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Vključevanje udeležencevFaza 2
- Stanford Cancer Institute, Palo Alto · 5 mi stran
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- Palo Alto Medical Foundation Research Center, Palo Alto · 5 mi stran
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Vključevanje udeležencevFaza 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi stran
- in še 1
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Vključevanje udeležencevFaza 2
- Stanford University, Stanford · 5 mi stran
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Vključevanje udeležencevFaza 2/3
- Local Institution - 0358, Stanford · 5 mi stran
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Vključevanje udeležencevFaza 3
- Stanford Medicine Cancer Center - Stanford Women's Cancer Center, Palo Alto · 5 mi stran
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Vključevanje udeležencevFaza 1
- Stanford University Medical Center, Palo Alto · 5 mi stran
Magnetic Resonance Imaging of Breast Cancer
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Stanford University School of Medicine, Stanford · 5 mi stran
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Vključevanje udeležencevOpazovalna študija
- Stanford University School of Medicine, Stanford · 5 mi stran
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Vključevanje udeležencevFaza 3
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5 mi stran
- Stanford Cancer Institute Palo Alto, Palo Alto · 5 mi stran
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1
- Stanford Cancer Institute, Stanford · 5 mi stran
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Vključevanje udeležencev
- Stanford University, Stanford · 5 mi stran
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Vključevanje udeležencevOpazovalna študija
- Stanford Cancer Institute, Palo Alto · 5 mi stran
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Stanford · 5 mi stran
Študije za Rak dojke v drugih mestih
- New York City, NY136 študij
- Houston, TX126 študij
- Boston, MA112 študij
- Nashville, TN81 študij
- Los Angeles, CA73 študij
- Edison, NJ68 študij
- St. Louis, MO64 študij
- Queens, NY64 študij
- Durham, NC64 študij
- Chicago, IL59 študij
- Philadelphia, PA56 študij
- Dallas, TX55 študij
Druge študije v Mountain View
- Rak (vse vrste)40 študij
- Metastatski rak25 študij
- Nemalicelični pljučni rak21 študij
- Akutna mieločna levkemija19 študij
- Rak jajčnikov19 študij
- Motnja avtističnega spektra17 študij
- Rak pljuč17 študij
- Rak prostate15 študij
- Srčno popuščanje15 študij
- Avtizem13 študij
- Akutna limfoblastna levkemija13 študij
- Kolorektalni rak13 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.